IPO News Archive

Verastem prices upsized IPO at $10 midpoint

1/26/12


Verastem, a pre-clinical stage biotech developing stem cell therapies for metastatic cancers, raised $55 million by offering 5.5 million shares at $10, the midpoint of the range of $9 to $11. Verastem plans to list on the NASDAQ under the symbol VSTM. UBS Investment Bank and Leerink Swann acted as lead managers on the deal.

Keywords/Tickers: VSTM
Related Links: Recently Priced IPOs
Source: www.RenaissanceCapital.com
blog comments powered by Disqus
Attribution Policy: The information contained herein is proprietary and copyrighted. The media is welcome to use our information and ideas, provided that the following sourcing is included: Renaissance Capital, Greenwich, CT (www.renaissancecapital.com).
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital and/or the Global IPO Fund (symbol: IPOSX) may have investments in securities of companies mentioned.
Invest in Global IPO Fund
About Fund Prospectus Invest